Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The high expression of exosomal miR-485-3p correlated with tumor size greater than or equal to 1 cm, advanced clinical stage, extrathyroidal extension, BRAF mutation, and lymph node metastasis.
|
31721725 |
2020 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Objective:</b> The COMBI-AD trial demonstrated the efficacy and safety of dabrafenib and trametinib in combination vs placebo as adjuvant treatment of patients with BRAF V600E/K mutation-positive resected Stage IIIA (lymph node metastasis >1 mm), IIIB, or IIIC melanoma.
|
31223037 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Kruskal-Wallis test was used for the univariate correlation analyses and comparison of mutation rate and expression rate, and Chi-square test was used for the association of central lymph node metastasis with BRAF gene and TSHR.
|
30655754 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
|
30819583 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Meta-analysis showed significant association of BRAF V600E+/TERT+ co-mutations with lymph node metastasis, multifocality, distant metastasis, tumor recurrence, extrathyroidal extension, and dead of disease.
|
31300059 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
The incidence of lymph node metastasis were as follows: wild type (19.3%), ROS1 (72.8%), BRAF (55.5%), ALK (44.7%), HER2 (40%), RET (23.1%), KRAS (15.3%), EGFR (15.3%) and MET mutation (0%) (P < 0.001).
|
31319984 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Often BRAF mutated carcinomas demonstrate adverse histological features such as lymphovascular invasion, perineural invasion, tumour budding and lymph node metastases.
|
30592501 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report the case of a 52-year-old woman who had a history of recurrent melanoma on her right shoulder with axillary lymph node metastasis (BRAF V600K-mutated melanoma) and right-side breast-invasive ductal carcinoma (stage pT1b N0sn).
|
30562218 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E was associated with aggressive tumor factors, including lymph node metastasis (P=0.001) and advanced disease stage (P=0.009).
|
31602213 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Statistical analysis demonstrated that the BRAF mutation rate was not associated with any of the following clinicopathological features: Sex, age, smoking history, clinical stages, distant metastasis, differentiation degree, tumor size and regional lymph node metastasis (P≥0.05).
|
29467863 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results showed that BRAF mutation was associated with a larger tumor size, higher frequency of lymph node metastasis, and lower TIMP3 protein levels.
|
29868127 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
|
29560564 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Univariant analysis indicated that capsular invasion, Hashimoto's thyroiditis, multifocal loci, central lymph node metastases as well as BRAF mutation predicted a high incidence of occult contralateral carcinoma.
|
29083503 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study showed that there was no significant association of BRAF V600E mutation with the gender, age, tumor size and lymph node metastasis in PTCs.
|
29254799 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One case not meeting criteria for NIFTP maintained the diagnosis of encapsulated FVPTC without invasion but demonstrated significant mitotic activity (three mitoses/ten HPF) and lacked lymph node metastases and BRAF V600E mutation.
|
29368294 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present a case of a woman with BRAF V600E-mutated malignant melanoma and rapidly progressing liver, bone, and lymph node metastases.
|
29215399 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
EphB3 expression was negatively associated with invasive depth (P = 0.016, r<sub>s</sub> = -0.213), lymph node metastasis (P = 0.000, r<sub>s</sub> = -0.490), and TNM stage (P = 0.000, r<sub>s</sub> = -0.390), and was positively associated with poor differentiation (P = 0.001, r<sub>s</sub> = 0.290), BRAF V600E mutation (P = 0.008, r<sub>s</sub> = 0.235), and longer overall survival (P < 0.001).
|
30535864 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CONCLUSIONS Expression of the BRAF V600E mutation and RET/PTC translocation promoted the activity of NF-κB, expression of inflammatory mediators, and lymph node metastases in patients with PTC.
|
30254191 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MMs lymph node metastasis (hazard ratio 2.54 [95% confidence interval 1.062 - 6.066], P = .01) affected survival.This study indicated that BRAF mutations and expression might serve as independent adverse prognostic factors in melanoma.
|
29505523 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association between central lymph node metastasis (LNM) and risk factors, including the presence of the BRAF mutation, BRAF<sup>V600E</sup>, in patients with papillary thyroid cancer (PTC) requires further investigation.
|
28943919 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the pediatric PTCs, BRAF <sup>V600E</sup> was positively associated with older age, classical histology, and the lymph node metastasis but independent from other clinicopathological factors.
|
28176151 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation was associated with lymph node metastasis (adjusted RRR 2.46 95% CI 1.07-5.69, P=0.04) and sentinel lymph node positivity (adjusted odds ratio [aOR] OR 1.55, 95% CI 1.14-2.10, P=0.005).
|
28787433 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.
|
28680105 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases.
|
29037218 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Its expression was related significantly to histopathological variants (P = 0.007), lymph node metastasis (P = 0.016), BRAF mutation (P = 0.036) and extent of surgery (P = 0.014).
|
27542980 |
2017 |